Fair Market Value and Payments to Healthcare Professionals – How Should We Determine What We Pay? © Huron Consulting Services LLC. All rights reserved.

Slides:



Advertisements
Similar presentations
4.02 Compliance Training Brian A. Dahl Senior Counsel Takeda Pharmaceuticals North America, Inc. November 14, 2003.
Advertisements

Professional Education Support Wyeth Pharmaceuticals Melinda Somasekhar, PhD.
1 1 Medicare Marketing Danielle R. Moon, J.D., M.P.A. Director, Medicare Drug & Health Plan Contract Administration Group National Association of Health.
EMS Checklist (ISO model)
POLICY AND OVERSIGHT DIVISION (POD) February 2014 Documentation of Evaluation for Award 1.
The Deficit Reduction Act, Deficit Reduction Act of 2005 In the Deficit Reduction Act of 2005 (DRA) Congress, for the first time, has mandated healthcare.
Bundled Pricing Medicare’s New Payment Model
Our Goals Today To help you feel comfortable with asking questions.
© 2007 Husch & Eppenberger, LLC1 L-3: New Government Source of Revenue: Fraud & Abuse Actions Expanded MARK REAGAN Hooper, Lundy & Bookman, Inc. San Francisco,
STRATEGIC PLANNING FOR Post-Clearance Audit (PCA)
Pharmaceutical Compliance Current Trends: Hot Button Issues to Look at this Year in Sales, Marketing, Clinical, Medical Affairs and Government Pricing.
© 2009 Cengage Learning. All Rights Reserved. Healthcare Fraud and Abuse.
BlueCare Tennessee and BlueCare, Independent Licensees of BlueCross BlueShield Association How the Deficit Reduction Act of 2005 Impacts BlueCare Tennessee.
2011 FRAUD & ABUSE UPDATE John Hellow Hooper, Lundy & Bookman, PC All views expressed in the seminar materials and.
Sales & Marketing Compliance Training
Medicare Parts C and D Fraud, Waste, and Abuse Compliance Training
Lori K. Nomura | AWPHD Administrator’s Only Retreat Trends in Hospital/Physician Relations and Corporate Compliance May 22-24,
Regulatory Control of Providers Financial Relationships Civil False Claims The Act.
1 Certification Chapter 14, Storey. 2 Topics  What is certification?  Various forms of certification  The process of system certification (the planning.
Maryland State Bar Association Health Law Section Understanding Medicare Billing Issues: Anti-Markup Rules, Independent Diagnostic Testing Facility Rules,
Fraud, Waste & Abuse DEFICIT REDUCTION ACT OF 2005 Presented by: MARCH Vision Care, 2013.
The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Compliance Best Practices in a Post Orthopedic Environment David Matyas.
Physician Preference Items: A New Paradigm By John M. McGuire President & CEO Surgical Implant Services, LLC.
# Operating Under the New Compliance Environment: Considerations for the Pharmaceutical Industry The Impact of the new Medicare Prescription Drug benefit.
False Claims Act and Whistleblower Protections False Claims Act and Whistleblower Protections Genetic Disease Screening Program Employee Education and.
© 2009 The McGraw-Hill Companies, Inc. All rights reserved. 1 McGraw-Hill Chapter 5 HIPAA Enforcement HIPAA for Allied Health Careers.
Medicare Advantage & Part D Compliance Training 2009.
COMPLIANCE PROGRAM. Agenda  Initial Scenarios  Review of General Compliance Information  Review UCP’s Compliance Program  Questions and Discussion.
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
MassMEDIC February 26, 2010 Licensing and Compliance Presenter David L. Cavanaugh 60 State Street Boston, MA Pennsylvania Avenue, NW Washington,
Blue Cross of Idaho Medicare Advantage Provider Fraud, Waste and Abuse Training Fall 2009.
Engineering Ethics.
Copyright ©2011 by Pearson Education, Inc. Upper Saddle River, New Jersey All rights reserved. Pearson's Comprehensive Medical Assisting: Administrative.
Pharmaceutical Regulatory & Compliance Congress Washington, DC November 9, 2006 Fair Market Value Considerations in Industry Relationships Wendy C. Goldstein,
1 Strategies for a Compliant Grant Process CIA Monitoring Obligations A. Monica Jonhart Director-U S Pharmaceuticals Compliance Bristol-Myers Squibb.
Medicare and Patient Assistance Sean M. Dougherty Senior Director Medicare Strategy & Patient Assistance Programs Government, Public Policy And Managed.
Sales and Marketing in the Pharmaceutical Industry: At the Vortex of the Perfect Legal Storm Paul E. Kalb, M.D., J.D. Princeton, N.J. - June 7, 2004.
Fraud and Abuse in Dentistry. Definition Fraud is the intentional perversion of truth in order to induce another to part with something of value, or surrender.
RISK MANAGEMENT IN THE TREATMENT OF OPIOID DEPENDENCE Presented by: Barbara A. M. Maloney, Esq.
Key Compliance Risks in Clinical Trials Kathleen Meriwether Principal, ERNST & YOUNG, LLP Fraud Investigation & Dispute Services.
Vendor Relations Policy. Why Is There A Policy? The Patient Protection and Affordable Care Act was signed into law March 23, The new law contains.
A Focus on CME and Grants Nancy Coddington, PhD Senior Director, Compliance Operations AstraZeneca Pharmaceuticals LP And Terry Hisey Deputy Managing Principal.
Bona Fide Service Fees Context –Impact of arrangements with Distributors/Wholesalers on Government Pricing Calculations Letter to HDMA re fee-for-service.
Managing the Money Trail in the Research Environment Seth B. Whitelaw Compliance Officer, Global R&D GlaxoSmithKline 14 November 2002.
1 Continuing Medical Education and Industry Sponsorship The Pharma, Biotech and Device Colloquium Princeton, NJ June 7, 2005 Julie K. Taitsman, M.D., J.D.
1 Harvard University Cambridge, MA March 29, 2007 Medical Device Congress AdvaMed’s Efforts to Promote Compliance Christopher L. White, Esq. Executive.
Welcome General Compliance Training.  To inform you who to contact to ask questions  To let you know that you are responsible to disclose  To share.
1 Pharmacy Management and Cost-Containment: Pharmaceutical Fraud Investigations, Prosecutions and Compliance Strategies John T. Bentivoglio
Overview of Huron and the International Medical Device Compliance Code Compendium The Second Annual Medical Device Regulatory, Reimbursement and Compliance.
Compliance Issues in Dealing With Drug and Device Manufacturers Presentation to The Sixth Annual National Congress On Health Care Compliance Paul E. Kalb,
California Department of Public Health / 1 CALIFORNIA DEPARTMENT OF PUBLIC HEALTH Standards and Guidelines for Healthcare Surge during Emergencies How.
Ethical Issues for Medical Writers DARSHAN KULKARNI PHARM.D., MS, ESQ. KULKARNI LAW FIRM Kulkarni Law Firm 1.
1 The Implementation of Fair Market Value What can we learn from recent enforcement actions? Debjit Ghosh Life Sciences Advisory Services Huron Consulting.
Chapter 4 The Legal and Regulatory Environment of Health Care.
The Legal Context of Business
The Legal Context of Business
Compliance and Enforcement Roundtable Discussion
Action Items: Monitoring Off-Label Promotion Do’s and Don’t’s
How to Apply for and Receive Industry Funding for Investigator Sponsored Research Chuck Simonton MD, FACC, FSCAI Chief Medical Officer Abbott Vascular.
RISK MANAGEMENT IN THE TREATMENT OF OPIOID DEPENDENCE
FRAUD, WASTE, & ABUSE (FWA) 2012
PHARMA AUDIOCONFERENCE An Analysis of the HHS OIG Draft Compliance Program Guidance for the Pharmaceutical Industry Overview of Draft CPG Michael P.
Pre-Close Rules of Engagement
Multiple Employer Welfare Arrangement (MEWA)
Compliance Program 2018.
Medical Device Industry Update Overview of the Stark Laws
What Every Employee Should Know About Compliance.
COMPLIANCE PROGRAM.
Brussels, June 6, 2007 Paul E. Kalb, M.D., J.D.
Implementing Controls Around Grants, Consulting Agreements, CME, Preceptorships, and Other Promotional Practices Paul E. Kalb Heidi C. Chen Fourth Annual.
Presentation transcript:

Fair Market Value and Payments to Healthcare Professionals – How Should We Determine What We Pay? © Huron Consulting Services LLC. All rights reserved.

2 Contact Information Debjit Ghosh Life Sciences Practices Huron Consulting Group 1120 Avenue of the Americas New York, NY (P)

3 The Regulatory Environment

4 Evaluating the Appropriateness of Payments With increased prosecution targeting Medical Device, Pharmaceutical and Biotechnology companies under the Anti-Kickback Statute and the False Claims Act, formal assessments of bona fide service and fair market value can be a critical step in substantiating the appropriateness of payments by manufacturers to various constituents in the healthcare supply chain. Sales & Marketing Healthcare Professionals Training Medical Education Grants Commercial Contracting Payors Distributors Authorized Agents Clinical Research Institutions Hospitals Clinics Physician Practices

5 The Regulatory Environment Regulatory bodies are increasingly scrutinizing payments made by Medical Device, Pharmaceutical and Biotechnology Companies to healthcare professionals: Centers for Medicare and Medicaid Services; HHS Office of Inspector General; Department of Justice; State Attorneys General. Key risk areas: Are these payments potential inducements for product selection? Could these payments be construed as a kickback or part of a quid pro quo arrangement? Did these payments potentially initiate use of the product inappropriately? Risk management for Medical Device Companies: Demonstrate that the payments are for bona fide purposes. Demonstrate that the payments represent fair market value.

6 Direct Payment Risks to Healthcare Professionals Direct payments to or involving healthcare professionals generally draws the greatest amount of scrutiny. Payments to any individual in a position to influence a referral is a key compliance risk area. Regulators are broadly concerned about gifts, hospitality, and charitable contributions. However, fee-for-service arrangements are also of concern: Providing product training Participation in Advisory Boards Payments to act as a Speaker or be involved in Speaker Training Market Research Consulting arrangements Medical Education or CME events Manufacturers must also be concerned with Agents and Authorized Representatives.

7 The Broad Application of Fair Market Value The principles of demonstrating bona fide purpose and fair market value should not be limited to direct payments to healthcare professionals, but to all payments made into the healthcare supply chain. Regulators are issuing broad document requests to examine all types of financial relationships between life science companies and their partners in the healthcare system. This could include any entity that either employs or is a conduit to a healthcare professional: Research Grants Medical Education and Training Contracts with Distributors

8 Implications to State Law Compliance Pharmaceutical companies are facing a myriad of compliance challenges from various State Laws that legislate compliance for sales & marketing activities such as: CA, MN, VT, ME, etc. Although most laws are strictly directed at Pharmaceutical Companies, a number of State Attorneys General along with the OIG have made references where they do not draw distinctions for the purposes of sales & marketing. If the States expand their compliance tracking and reporting initiatives to include Medical Device Manufacturers, then formal tracking of spending on healthcare professionals will be a critical activity. Distinguishing fee-for-service payments to healthcare professionals will be a critical as each of the State laws provide tracking and reporting exemptions for bona fide payments that do not exceed fair market value.

9 The Legal Framework

10 The Anti-Kickback Statue The anti-kickback statute is a criminal prohibition against payments (in any form, whether the payments are direct or indirect) made purposefully to induce or reward the referral or generation of federal healthcare business – HHS OIG. Although liability under the anti-kickback statute ultimately turns on a partys intent, it is possible to identify arrangements or practices that may present a significant potential for abuse – HHS OIG. Manufacturers, providers and suppliers of health care products and services frequently cultivate relationships with physicians in a position to generate business for them through a variety practices, including gifts, entertainment, and personal services compensation arrangements. These activities have a high potential for fraud and abuse and, historically, have generated a substantial number of anti-kickback convictions – HHS OIG.

11 The False Claims Act What does it prohibit? Any person who presents, or causes to be presented a claim for payment or approval to the federal government that was false or fraudulent and defendant acted knowingly violates that statute. What is knowingly? Has actual knowledge of the information: Acts in deliberate ignorance of the truth or falsity of the information; or Acts in reckless disregard of the truth or falsity of the information; NO PROOF OF SPECIFIC INTENT TO DEFRAUD IS REQUIRED! What are the penalties? Civil penalty of not less than $5,500 and not more than $11,000 for each claim plus Up to 3 times the amount of damages which the government sustains. Who enforces the False Claims Act? The United States Department of Justice enforces the False Claims Act. Under the qui tam provisions of the False Claims Act, private parties who have direct knowledge of the fraud can file an action on behalf of the government. –These individuals are referred to as relators or whistleblowers. –They are like private attorney generals –Relators can proceed with a case even if the government declines to intervene in the case. –Qui tam relators receive a portion of proceeds depending on level of involvement and other factor.

12 The Approach to Valuation

13 Fair Market Value Fair market value is often defined as: …the price at which the items or services would be exchanged between a willing buyer and a willing seller, neither being under any compulsion to buy or sell and both having reasonable knowledge of the relevant facts, and without consideration of either partys position to make or influence referrals, to furnish items or services to, or otherwise generate business for the other party as of the Date of Valuation.

14 Performing a Bona Fide Service Fee Analysis Generally there isnt much purpose to determining fair market value if you have not determined if the fee is for a bona fide purpose. Perform supporting analysis What is the specific purpose of the payment? Is there formal agreement/contract governing the service? Is the fee broken down to its basic components? Is it duplicative with any existing functions within the company or payment made by another part of the company? Is the payment directly related to the companys commercial or clinical strategy? Is there a formal process through which the payment is approved? Are there controls in place to prevent fraud, waste, and abuse? Document the process, purpose, need, payment, and service (PPNPS)

15 PPNPS – 5 Critical Elements to Documentation Process Is there a formal process through which payment levels are determined through pre-specified criteria? Are the payments pre-set and defined or can they be variable? Purpose Why is the payment necessary? What is the underlying purpose? Is the payment potentially duplicative? Is there a potential for fraud, waste, and abuse? Need Why is the service necessary from this individual or company? How does it relate to the companys commercial or clinical strategy? Payment Was there a determination process to derive a fair market value range for the payment? Is there a process to track the totality of spend on a particular healthcare professional? Service Was the service actually performed? Was there a demonstrable outcome that resulted from the payment?

16 Assessing Fair Market Value The HHS OIG has identified payments to healthcare professionals as compliance risk areas; however, they do not establish fair market value payment rates nor define a procedure or calculation to derive this value. Develop ranges of Fair Market Value payment rates to be used as a guideline in the establishment of service fee agreements. Regulatory agencies provide little guidance – specific facts and circumstances dictate appropriate approach and methodologies. Typically, the cost and market approaches are used to value service agreements, with income approach utilized as corroboration. Whenever possible, fair market value payment rates should be analyzed and developed using multiple valuation approaches.

17 Valuation Basics – Three Established Approaches Cost build-up approach In applying the cost approach to services, a cost build-up approach is often utilized. Under the cost build-up approach, actual or expected costs incurred are analyzed and an assumed profit level is estimated to derive an indication of the fair market value of the services. Income approach In applying the income approach to services, analyses of various rates of return provide corroboration for estimated fair market values. Market approach In applying the market approach we are looking for agreements involving the sale of similar services. This market data is adjusted for significant differences. Based on types of services provided, data provided, pricing for services can greatly impact value and lead to appropriate adjustments. –Services provided by outside companies – Outsourcing functions (e.g., sales force training, contract enrollment and administration, call center support, data fees); –Services performed in similar settings or environments; and –Industry knowledge from other projects of a similar nature.

18 Performing Valuation Analysis Valuation theory provides three broad approaches to developing data and analysis pertinent to the goods or services that are being valued (Cost, Income, and Market). However, valuation analysis itself is very specific to the facts and circumstances that are presented. Fair market value for one company may not represent fair market value for another. In general, a customized approach is developed to meet the specific valuation need. In most cases, one approach tends to emerge as the most appropriate methodology for the valuation analysis. In such cases, the other two approaches, when feasible are used to corroborate the analysis. Development of an appropriate fair market value payment rate generally considers the following: Understanding the nature of the contracted services, the competitive landscape of the marketplace, and analogous goods and services provided within the industry and from other industries; Gather and analyze Company data; Gather and analyze market data; and Consider general knowledge of industry best practices.

19 Sample Case Study What is the context of the service? Are we asking the HCP to forgo leisure time? Are we asking the HCP to forgo professional time? Will the HCP be losing revenue? How much time is required to perform the service? How much time is required to prepare to perform the service? Does the HCP need to travel to perform the service? Should a premium be assigned to perform the service? What is the competitive landscape? Are there downstream revenue opportunities? Payments to Healthcare Professionals